Given the number of comorbidities associated with obesity, the market's growth will impact the entire cardiometabolic disease ...

Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The ...

Given the number of comorbidities associated with obesity, the market's growth will impact the entire cardiometabolic disease ...

A broad measure of Asian equities slipped, pressured by sell-offs in Hong Kong and mainland China. Futures for the S&P 500 ...

Eli Lilly’s profit doubled in ... better-than-expected 2025 forecast. Sales of Lilly’s top-selling product, the diabetes treatment Mounjaro, jumped 60% to $3.53 billion in the final quarter ...

Eli Lilly has begun the week with a bang ... Tirzepatide, the GLP-1 drug in Mounjaro and Zepbound, is Lilly’s highest-profile MASH candidate. Lilly reported phase 2 MASH data in June and ...

The 200-acre Lilly Medicine Foundry is expected to add 400 full-time jobs for highly skilled workers, including engineers, ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE ... driven by strong volume growth from Mounjaro and Zepbound. Earnings per share (EPS) for the quarter doubled ...

One of the highlights of Eli Lilly's third-quarter results was the rapid uptake of new type 2 diabetes therapy Mounjaro, which added more than $97 million in US sales alone in what has been ...

Eli Lilly, the American company that makes a rival weight-loss drug called Mounjaro, has also called for the obesity drugs to be listed on the PBS in its pre-budget submission. The Eli Lilly ...

Eli Lilly should continue to grow its top line faster than its similarly sized peers. Its lineup features several blockbusters, including its popular diabetes and weight loss medicines ...